Published in Horm Metab Res on November 01, 1975
The histocompatibility system in juvenile, insulin-dependent diabetic multiplex kindreds. J Clin Invest (1977) 2.01
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia (2008) 4.62
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
DNA commission of the International Society of Forensic Genetics: Recommendations on the interpretation of mixtures. Forensic Sci Int (2006) 3.20
Borna disease: a persistent virus infection of the central nervous system. Prog Med Virol (1988) 2.83
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A (1994) 2.74
Hypomagnesaemia in type 2 (non-insulin-dependent) diabetes mellitus is not corrected by improvement of long-term metabolic control. Diabetologia (1992) 2.72
Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A (1992) 2.44
Repetitive sequences in complete and defective genomes of Herpesvirus saimiri. J Virol (1975) 2.36
Borna disease virus genome transcribed and expressed in psychiatric patients. Nat Med (1995) 2.30
The challenge of biosimilars. Ann Oncol (2007) 2.28
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23
DNA Commission of the International Society of Forensic Genetics (ISFG): an update of the recommendations on the use of Y-STRs in forensic analysis. Forensic Sci Int (2006) 2.22
Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia (1983) 2.18
Identification of a common antigen of herpes simplex virus bovine herpes mammillitis virus, and B virus. J Virol (1978) 2.16
Interleukin-6 is a prognostic factor in multiple myeloma. Blood (1991) 2.16
Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost (1994) 2.09
A viro-psycho-immunological disease-model of a subtype affective disorder. Pharmacopsychiatry (1998) 2.08
DNA Commission of the International Society of Forensic Genetics (ISFG): an update of the recommendations on the use of Y-STRs in forensic analysis. Int J Legal Med (2006) 2.00
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab (2014) 1.99
Nomenclature for factors of the HLA system, 1990. Tissue Antigens (1991) 1.98
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood (1998) 1.90
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem (2000) 1.87
Physicochemical properties of the DNA of herpes viruses. Biochim Biophys Acta (1972) 1.86
First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry (1996) 1.83
A simple method for measuring red cell deformability in models of the microcirculation. Blut (1973) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Sequence conservation in field and experimental isolates of Borna disease virus. J Virol (1994) 1.67
Detection of new DNA polymerase genes of known and potentially novel herpesviruses by PCR with degenerate and deoxyinosine-substituted primers. Virus Genes (1999) 1.65
Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes (2009) 1.65
Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet (1997) 1.62
Persistent, tolerant or subacute infection in Borna disease virus-infected rats. J Gen Virol (1983) 1.62
Cerebrovascular tone rather than intracranial pressure determines the effective downstream pressure of the cerebral circulation in the absence of intracranial hypertension. J Neurosurg Anesthesiol (2000) 1.61
Clp-mediated proteolysis in Gram-positive bacteria is autoregulated by the stability of a repressor. EMBO J (2001) 1.61
Borna disease--neuropathology and pathogenesis. Curr Top Microbiol Immunol (1995) 1.59
Nomenclature for factors of the HLA system, 1991. WHO Nomenclature Committee for factors of the HLA system. Tissue Antigens (1992) 1.58
Nomenclature for factors of the HLA system, 2004. Tissue Antigens (2005) 1.57
Borna disease virus-specific antibodies in patients with HIV infection and with mental disorders. Lancet (1988) 1.57
Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G. J Pediatr (2000) 1.51
Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab (2014) 1.51
Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev (2008) 1.50
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.47
Paternity Testing Commission of the International Society of Forensic Genetics. Recommendations on genetic investigations in paternity cases. Int J Legal Med (2003) 1.46
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol (2003) 1.44
Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia (2008) 1.42
Rheumatoid arthritis and B lymphocyte alloantigen HLA-DRw4. J Rheumatol (1980) 1.41
Immunologic and genetic relationship between herpes simplex virus and bovine herpes mammillitis virus. Intervirology (1974) 1.41
[Lispro-insulin analogs in therapy of diabetes]. Wien Klin Wochenschr (1997) 1.40
Nomenclature for factors of the HLA system, 1998. Tissue Antigens (1999) 1.40
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol (2000) 1.39
[The HL-A-system in paternity testing (author's transl)]. Z Rechtsmed (1974) 1.39
Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Ann Oncol (2009) 1.39
Night time blood pressure in diabetic patients--the submerged portion of the iceberg? Nephrol Dial Transplant (1999) 1.39
Universal leucocyte-depletion of blood components: cell concentrates and plasma. Vox Sang (2001) 1.39
Defective macrophage function in a patient with common variable immunodeficiency. N Engl J Med (1982) 1.38
Specificity of cleavage in replicative-form DNA of bovine herpesvirus 1. J Virol (1988) 1.34
Nomenclature for factors of the HLA system, 1995. Tissue Antigens (1995) 1.34
Borna disease in ostriches. Vet Rec (1993) 1.34
Studies on the relatedness of herpes viruses through DNA-RNA hybridization. Biochim Biophys Acta (1972) 1.31
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol (2012) 1.31
HLA antigens in inflammatory bowel disease. Gastroenterology (1982) 1.31
Immunoprecipitation of herpes simplex virus type 1 antigens with different antisera and human cerebrospinal fluids. Arch Virol (1977) 1.30
The relation of parental sex and age to recombination in the HL-A system. Hum Hered (1973) 1.30
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
[Borna virus infection (Borna disease) in naturally and experimentally infected animals: its significance for research and practice]. Tierarztl Prax (1985) 1.29
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia (2005) 1.29
Behavior alterations in tree shrews (Tupaia glis, Diard 1820) induced by Borna disease virus. Med Microbiol Immunol (1978) 1.29
DNA commission of the International Society of Forensic Genetics: recommendations on forensic analysis using Y-chromosome STRs. Int J Legal Med (2001) 1.28
Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant (2005) 1.28
Analysis of herpes simplex virus type 1 antigens exposed on the surface of infected tissue culture cells. Virology (1978) 1.28
DNA Commission of the International Society for Forensic Genetics (ISFG): recommendations regarding the role of forensic genetics for disaster victim identification (DVI). Forensic Sci Int Genet (2006) 1.28
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer (1994) 1.25
[Immunologic types of lymphocytes in acute lymphatic leukemia during remission (author's transl)]. Padiatr Padol (1975) 1.25
The characterization of Varicella-zoster virus DNA. J Gen Virol (1972) 1.23
Adaptation of Borna disease virus to the mouse. J Gen Virol (1984) 1.23
Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia (1988) 1.23
Human infections with Borna disease virus: seroprevalence in patients with chronic diseases and healthy individuals. J Med Virol (1992) 1.22
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia (2006) 1.22
Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang (2003) 1.22
Nomenclature for factors of the HLA system, 2000. Tissue Antigens (2001) 1.21
HLA-DR and Hashimoto's thyroiditis. Tissue Antigens (1980) 1.20
Increase of virus yields and releases of Borna disease virus from persistently infected cells. Virus Res (1985) 1.20
Nomenclature for factors of the HLA system, 1994. Tissue Antigens (1994) 1.19
Natural Borna disease in domestic animals others than horses and sheep. Zentralbl Veterinarmed B (1993) 1.18
The ionic properties of the filamentous bacteriophages Pf1 and fd. J Biol Chem (1986) 1.18
Nomenclature for factors of the HLA system, 1996. Tissue Antigens (1997) 1.18
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev (2005) 1.18
[Autoimmune phenomena in D-penicillamine therapy]. Acta Med Austriaca (1975) 1.17
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia (2011) 1.17
Isolation and characterization of a 14500 molecular weight protein from brains and tissue cultures persistently infected with borna disease virus. J Gen Virol (1985) 1.17
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med (2005) 1.17
Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet (2000) 1.17
Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology (1993) 1.16